As world leaders gathered at Davos 2023 to discuss and address critical global issues, the impact and legacy of the COVID-19 pandemic was high on the agenda (https://www.gavi.org/vaccineswork/davos-2023-what-you-need-know-about-future-global-health). It highlighted the 6.7 million estimated death toll and over 680 million infections caused worldwide.
An additional long-term impact of the pandemic discussed at Davos is the estimated 500 million additional antibiotic courses administered to the majority of COVID-19 infection sufferers. This has added to the increasing growth in antibiotic resistance and highlighted the need for innovative alternatives to antibiotics to help slow the impact of this global healthcare issue.
Destiny Pharma’s XF platform offers a novel mechanism of action that addresses AMR in infection prevention.